Loading...
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer.
Von Rohr, A Anderson, Heather McIntosh, R Thatcher, Nick
Von Rohr, A
Anderson, Heather
McIntosh, R
Thatcher, Nick
Citations
Altmetric:
Abstract
In a phase II study of non-small cell lung cancer a new chemotherapy combination of mitomycin 6 mg/m2 intravenously on day 1, carboplatin 400 mg/m2 intravenously on day 1 and ifosfamide with mesna 5 g/m2 intravenously over 24 hours on day 1 was evaluated. A maximum of four chemotherapy cycles was given at intervals of 4 weeks to 34 patients with progressive, inoperable disease. 1 complete and 10 partial remissions were documented, the overall response rate being 32.4%. In a further 13 patients (38.2%) the previously progressing tumours remained stable for at least 6 weeks. The median time to progression for responding patients was 184 days. The median survival time for the whole group has not yet been reached at 293 days. A considerable but easily manageable myelosuppression was the principal toxicity despite a "no dose reduction" policy. Indeed, the dose intensity of the chemotherapy actually given was extremely close (97%) to that intended on protocol. In conclusion, the regimen is active in patients with advanced non-small cell lung cancer but requires regular haematological monitoring to prevent morbidity resulting from myelotoxicity.
Description
Date
1991
Publisher
Collections
Keywords
Haematologic Diseases
Lung Cancer
Lung Cancer
Type
Article
Citation
Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. 1991, 27 (9):1106-8 Eur. J. Cancer